Clint Howell, PA
Medical · Norman, OKNPI 1174878433
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 647 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,907, 2.4 times the $1,623 reported in 2021. Among medical clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 647 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Johnson & Johnson$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Gilead$629
- Madrigal Pharmaceuticals$622
- plus $3K from 27 others
What the payments were for
- Food & beverage$10,27999%
- Education$1541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 126 | $1,849 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 116 | $1,620 |
| Johnson & Johnson | 99 | $1,509 |
| Takeda Pharmaceuticals U.S.A., Inc. | 74 | $1,201 |
| Gilead | 40 | $629 |
| Madrigal Pharmaceuticals | 23 | $622 |
| Lilly USA, LLC | 15 | $381 |
| QOL Medical, LLC | 16 | $316 |
| Sanofi | 16 | $254 |
| Aimmune Therapeutics, Inc. | 10 | $214 |
| Ipsen Biopharmaceuticals, Inc | 15 | $203 |
| Daiichi Sankyo Inc. | 11 | $167 |
| Ardelyx, Inc. | 10 | $164 |
| Pfizer | 8 | $139 |
| Bristol Myers Squibb | 9 | $139 |
| Regeneron Healthcare Solutions, Inc. | 7 | $139 |
| Phathom Pharmaceuticals, Inc. | 8 | $127 |
| Ironwood Pharmaceuticals, Inc | 7 | $107 |
| Intercept Pharmaceuticals, Inc. | 7 | $106 |
| Organon | 5 | $78 |
| Nestle Healthcare Nutrition Inc. | 4 | $68 |
| Redhill Biopharma Inc. | 4 | $66 |
| Blueprint Medicines Corporation | 3 | $60 |
| Celltrion USA Inc. | 2 | $44 |
| Boston Scientific | 3 | $44 |
| Merck | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 1 | $33 |
| Amgen | 1 | $28 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Vyaire Medical, Inc. | 1 | $18 |
| Vivus LLC | 1 | $16 |
How this compares
$10,432 in reported general payments places this provider in the 95th percentile of 370 medical providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SucraidSacrosidase | 28 | $384,421 |
| CreonLipase/Protease/Amylase | 59 | $172,501 |
| Humira(Cf) PenAdalimumab | 15 | $105,771 |
| XifaxanRifaximin | 33 | $96,775 |
| LinzessLinaclotide | 146 | $93,470 |
| ZenpepLipase/Protease/Amylase | 25 | $76,502 |
| TrulancePlecanatide | 44 | $34,550 |
| RelistorMethylnaltrexone Bromide | 14 | $33,446 |
| IbsrelaTenapanor Hcl | 16 | $27,005 |
| Dexlansoprazole DrDexlansoprazole | 78 | $20,687 |
| Mesalamine | 35 | $14,580 |
| MotegrityPrucalopride Succinate | 19 | $12,719 |
| Erythromycin Ethylsuccinate | 15 | $10,870 |
| VoqueznaVonoprazan Fumarate | 13 | $8,743 |
| MovantikNaloxegol Oxalate | 14 | $6,005 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| QOL Medical, LLCSucraid | $316 | $384,42128 claims |
| AbbVieCreon, Linzess | $1,849 | $265,971205 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Relistor, Plenvu | $1,620 | $168,386118 claims |
| Aimmune Therapeutics, Inc.Zenpep | $214 | $76,50225 claims |
| Ardelyx, Inc.Ibsrela | $164 | $27,00516 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $1,201 | $12,71919 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $127 | $8,74313 claims |
| Redhill Biopharma Inc.Movantik | $66 | $6,00514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 370 medical providers in Oklahoma.
Other medical in Norman
- Megan HutchersonNorman$7K
- Madison KearneyNorman$6K
- Mebin ThomasOklahoma City$323K
- Kelle ChristiansonMidwest City$117K
- Kristine MurrowOklahoma City$81K
- Matthew DohlmanTulsa$39K
- Katelyn PuryearOklahoma City$22K
- Tara LinvilleTulsa$19K
- Debra OdomTulsa$17K
- Donna BowersTuttle$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.